Black Diamond Therapeutics (BDTX) Retained Earnings (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Retained Earnings for 9 consecutive years, with $579.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 1.06% year-over-year to $579.8 million; the trailing twelve-month figure through Jun 2026 stood at $579.8 million (up 1.06% YoY), and the FY2025 full-year result was $576.8 million, up 1.14% from the prior year.
• Retained Earnings steadied at $579.8 million in Q2 2026 per BDTX's latest filing, from $578.1 million in the prior quarter.
• Across five years, Retained Earnings topped out at $579.8 million in Q2 2026 and bottomed at $443.7 million in Q1 2022.
• Historically, Retained Earnings has averaged $526.4 million across 5 years, with a median of $553.4 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings advanced 23.77% in 2024, then increased 1.05% in 2026.
• Over 5 years, Retained Earnings stood at $452.5 million in 2022, then rose by 18.05% to $534.2 million in 2023, then advanced by 6.77% to $570.4 million in 2024, then grew by 1.14% to $576.8 million in 2025, then gained by 0.52% to $579.8 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $579.8 million, $578.1 million, and $576.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.